Epkinly plus rituximab and lenalidomide is the first bispecific antibody combination FDA-approved for relapsed or refractory follicular lymphoma, backed by Phase III data showing substantially ...

Emerging applications of AI/ML, automation, and digitization are helping sponsors cut clinical trial start-up times to as little as four weeks, reduce data errors, and enhance patient ...

Understand the regulatory and policy considerations for running clinical trial recruitment campaigns on nontraditional or ...

As clinical research evolves, integrated technologies are reshaping patient and site experiences through AI, remote monitoring, and next-generation telehealth. Join IQVIA experts Chris Driver and Dan ...